Sai Life Expands Bidar API Capacity to 700 KL
ECONOMY & POLICY

Sai Life Expands Bidar API Capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), a contract research, development, and manufacturing organisation (CRDMO) focused on pharmaceutical innovation, has announced the completion of Phase II of its new Production Block (PB-11) at its flagship API manufacturing facility in Bidar, Karnataka.
Phase I of PB-11, inaugurated in December 2024, added 110 kilolitres (KL) of capacity. With the addition of approximately 91 KL in Phase II during Q1 FY26, PB-11 now totals nearly 200 KL of reactor volume—making it the single largest production block at the site. This expansion increases Sai Life’s total installed reactor capacity at the Bidar facility to around 700 KL.

Commenting on the development, Krishna Kanumuri, CEO and Managing Director of Sai Life Sciences, stated, “This expansion is not just about capacity—it’s about scalability, reliability, and the ability to support clients as their needs evolve. We are enabling faster, more secure drug development by strengthening our commercial-scale API and intermediate manufacturing.”

PB-11 is a versatile block designed for the large-scale production of commercial products. Unit IV in Bidar serves as Sai Life’s core manufacturing hub, catering to highly regulated markets including the US, EU, and Japan.

Key features of the facility include:
  • 12 multipurpose production blocks totalling ~700 KL
  • Dedicated units for high-potency APIs (HPAPIs)
  • Advanced QC laboratories ensuring regulatory compliance
  • Capabilities such as lyophilisation, cryogenic and high-pressure reactions, and large-scale chromatography
The site has passed inspections by global regulatory bodies including the USFDA, Japan’s PMDA, and India’s CDSCO. As of March 2025, Sai Life’s manufacturing units had completed over 75 customer audits in the past three years—underscoring the company’s commitment to safety, quality, and regulatory excellence. 

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), a contract research, development, and manufacturing organisation (CRDMO) focused on pharmaceutical innovation, has announced the completion of Phase II of its new Production Block (PB-11) at its flagship API manufacturing facility in Bidar, Karnataka.Phase I of PB-11, inaugurated in December 2024, added 110 kilolitres (KL) of capacity. With the addition of approximately 91 KL in Phase II during Q1 FY26, PB-11 now totals nearly 200 KL of reactor volume—making it the single largest production block at the site. This expansion increases Sai Life’s total installed reactor capacity at the Bidar facility to around 700 KL.Commenting on the development, Krishna Kanumuri, CEO and Managing Director of Sai Life Sciences, stated, “This expansion is not just about capacity—it’s about scalability, reliability, and the ability to support clients as their needs evolve. We are enabling faster, more secure drug development by strengthening our commercial-scale API and intermediate manufacturing.”PB-11 is a versatile block designed for the large-scale production of commercial products. Unit IV in Bidar serves as Sai Life’s core manufacturing hub, catering to highly regulated markets including the US, EU, and Japan.Key features of the facility include:12 multipurpose production blocks totalling ~700 KLDedicated units for high-potency APIs (HPAPIs)Advanced QC laboratories ensuring regulatory complianceCapabilities such as lyophilisation, cryogenic and high-pressure reactions, and large-scale chromatographyThe site has passed inspections by global regulatory bodies including the USFDA, Japan’s PMDA, and India’s CDSCO. As of March 2025, Sai Life’s manufacturing units had completed over 75 customer audits in the past three years—underscoring the company’s commitment to safety, quality, and regulatory excellence. 

Next Story
Infrastructure Urban

VECV Sales Rise 7.8 Per Cent In May 2026

VE Commercial Vehicles recorded sales of 7,978 units in May 2026, compared to 7,401 units in May 2025, registering growth of 7.8 per cent. This included 7,789 units from the Eicher brand and 189 units from the Volvo brand.Eicher branded trucks and buses reported sales of 7,789 units during the month, up 7.3 per cent from 7,258 units a year earlier. In the domestic commercial vehicle market, Eicher sales rose 9.1 per cent to 7,375 units from 6,758 units in May 2025.Exports declined 17.2 per cent to 414 units from 500 units in the corresponding month last year. Volvo Trucks and Volvo Buses recor..

Next Story
Infrastructure Urban

Table Space Strengthens DESYN Leadership Team

Table Space has announced strategic leadership appointments within DESYN, its integrated Design and Build business, as it looks to strengthen operations across key enterprise and GCC markets in India. DESYN was launched as a strategic extension of Table Space’s workspace solutions portfolio to meet rising demand for agile, high-quality and rapidly deployable enterprise workspaces.Shruti Ookabhoy has joined DESYN as Executive Director and will lead the Design vertical, focusing on design capability, operational excellence and team development across markets. She brings over 22 years of experi..

Next Story
Infrastructure Transport

Concord Associate Bags Rs 2.79 Bn Kavach Order

Concord Control Systems said its associate company, Progota India, has received a Rs 2.79 bn domestic order from Indian Railways for the supply, installation, testing and commissioning of on-board Kavach 4.0 loco equipment.The order is scheduled for execution within 12 months and strengthens Concord’s role in India’s railway safety and signalling ecosystem. Kavach is India’s indigenous automatic train protection system, designed to improve operational safety by helping prevent signal passing at danger and reducing collision risks.Gaurav Lath, Joint Managing Director, Concord Control Syst..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement